



Universiteit
Leiden
The Netherlands

Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers

Ibrahim, I.S.; Bruckner, C.; Carrato, A.; Earl, J.; Inderson, A.; Cappel, W.H.D.T.; ... ; Vasen, H.F.

Citation

Ibrahim, I. S., Bruckner, C., Carrato, A., Earl, J., Inderson, A., Cappel, W. H. D. T., ... Vasen, H. F. (2019). Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers. *United European Gastroenterology Journal*, 7(5), 682-688. doi:10.1177/2050640619841989

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/119833>

Note: To cite this publication please use the final published version (if applicable).


Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers

United European Gastroenterology Journal
2019, Vol. 7(5) 682–688
© Author(s) 2019



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2050640619841989
journals.sagepub.com/home/ueg



Isaura S Ibrahim¹ , Catharina Brückner², Alfredo Carrato³, Julie Earl³, Akin Inderson¹, Wouter H de Vos tot Nederveen Cappel⁴, Ioannis Mintziras², Elvira Matthäi², Jens Figiel⁵, Martin Wasser⁶, Hans Moreau⁷, Bert Bonsing⁸, Emily P Slater², Detlef K Bartsch² and Hans FA Vasen¹

Abstract

Background: Widespread abdominal imaging has led to a substantial increase in the detection of incidentalomas. Currently, an increasing number of centers offer surveillance of the pancreas to individuals at high risk (IARs) of pancreatic ductal adenocarcinoma (PDAC).

Objective: The aims of this study were to evaluate the frequency and type of incidental findings in a magnetic resonance imaging (MRI)-based surveillance program for IARs for PDAC, and to discuss the benefit of detecting these lesions.

Methods: The outcome of MRI screening was reviewed in 568 individuals from three long-term pancreas surveillance programs conducted at three large European expert centers. All MRIs were studied in detail for the presence of incidental lesions.

Results: The most common lesions were liver cysts, renal cysts and liver hemangioma, which together comprised 75% of all lesions. Only five (0.9%) patients underwent surgery for a benign lesion. Cancer was detected in 11 patients (1.9%); early detection of tumors was beneficial in at least five cases.

Conclusion: The present study demonstrates that extrapancreatic incidentaloma is a common finding in IARs for PDAC, but rarely requires additional treatment. *CDKN2A-p16-Leiden* mutation carriers were the only patient group found to harbor a substantial number of cancers, and detection resulted in benefit in several cases.

Keywords

High-risk individuals, genetic predisposition, incidental findings, incidentaloma, PDAC, screening, surveillance

Received: 26 September 2018; accepted: 11 March 2019

Introduction

The widespread use of magnetic resonance imaging (MRI) and computed tomography (CT) has led to a substantial increase in the detection of incidental findings, more commonly referred to as incidentalomas. The most frequent and extensively described incidentalomas found with abdominal imaging are adrenal masses, liver cysts and renal cysts. The clinical

⁴Department of Gastroenterology & Hepatology, Isala Clinics, Zwolle, the Netherlands

⁵Department of Radiology, University Hospital Marburg, Marburg, Germany

⁶Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands

⁷Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands

⁸Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands

D.K.B. and H.F.A.V. share senior authorship of this work.

Corresponding author:

Isaura S Ibrahim, Leiden University Medical Center, Department of Gastroenterology & Hepatology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.

Email: i.s.ibrahim@lumc.nl

¹Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, the Netherlands

²Department of Visceral-, Thoracic- and Vascular Surgery, University Hospital Marburg, Marburg, Germany

³Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain

significance of these lesions is often unknown. The management of an incidentaloma depends on the site, size and type of the lesion. Several guidelines have been published with detailed recommendations for management of these lesions.¹⁻⁵ Experience has shown that with additional imaging and subsequent surgical intervention, most lesions prove to be benign. Currently, an increasing number of centers offer surveillance of the pancreas to individuals at high risk (IARs) of pancreatic ductal adenocarcinoma (PDAC), usually involving MRI and/or endoscopic ultrasonography (EUS).⁶⁻⁹ These IARs can be subdivided into two groups: (1) patients with an underlying gene defect associated with a high risk of PDAC, most commonly *BRCA2* or *CDKN2A* mutations, and (2) patients with a positive family history of PDAC, also known as familial pancreatic cancer (FPC). Detection of extrapancreatic incidental lesions in these high-risk groups may offer benefit if the lesion is (pre)malignant. However, if only benign lesions are found, additional imaging and surgical intervention might be a burden, especially in high-risk groups that already undergo surveillance for multiple cancers.

In the present study, we evaluated the frequency of extrapancreatic incidentalomas in large, long-term, prospective surveillance programs for PDAC at three European expert centers. The aims of this study were (1) to evaluate the occurrence and type of extrapancreatic incidental findings in these surveillance programs, and (2) to assess the benefit of detecting these lesions.

Methods

The current study was made possible through the collaboration of three tertiary referral centers: the Department of Surgery at Philipps University in Marburg, Germany, the Department of Medical Oncology at Ramon y Cajal University Hospital in Madrid, Spain, and the Department of Gastroenterology & Hepatology at Leiden University Medical Center in Leiden, The Netherlands. The study design was a retrospective evaluation of an ongoing prospective follow-up study.^{7,8,10} In Leiden, a surveillance program was initiated for carriers of a *CDKN2A-p16-Leiden* mutation in the year 2000. In Marburg a similar program was introduced, mainly for families with FPC, in 2002. In 2010 a surveillance program was initiated in Madrid for various high-risk groups. The surveillance tools included MRI and EUS of the pancreas. The total number of individuals, the characteristics of the various high-risk groups and the surveillance methods implemented at each center are summarized in Table 1.

All MRIs were studied in detail for the presence of incidental findings including cysts, solid lesions, focal nodular hyperplasia (FNH), hemangioma and cancers. For all patients with an incidental lesion, further information was collected on whether additional imaging, intervention or surgery was performed. The observation time was from the start of a screening program up to 1 January 2018. The study was approved by the ethics committees of the respective centers.

Table 1. Characteristics of participants ($n = 568$) in pancreas surveillance programs in three European expert centers.

	Leiden	Madrid	Marburg
Year started surveillance	2000	2010	2002
FPC	-	52	240
FDR with PC < 50	-	5	-
HBOC	-	19	-
<i>BRCA1</i> or 2 mutation carrier	-	1	14
Lynch syndrome	-	1	-
Familial adenomatous polyposis	-	-	1
<i>STK11</i> -mutation	-	-	2
<i>CDKN2A-p16-Leiden</i> mutation	217	2	4
<i>PALB2</i> -mutation	-	-	7
FPC/Lynch Syndrome/HBOC	-	1	-
FPC/HBOC	-	2	-
Surveillance protocol	MRI with optional EUS since 2012	Annual MRI and EUS	Annual MRI and EUS every three years
Total number of IARs	217	83	268

EUS: endoscopic ultrasound; FDR: first-degree relative; FPC: familial pancreatic cancer; HBOC: hereditary breast ovarian cancer; IARs: individuals at high risk; MRI: magnetic resonance imaging; PC: pancreatic cancer.

Oral or written informed consent was received from all patients. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

Results

Leiden, the Netherlands

Of the 217 IARs under surveillance in Leiden during the study period, 214 were carriers of a *CDKN2A-p16-Leiden* mutation while three had a pathogenic variant in *CDKN2A*. Ninety-four were male (43.3%) and 123 (56.7%) female. The mean age at start of surveillance was 51.5 years (range, 36.2–72.2 years), with a median follow-up time of 4.7 years (range, 0.0–16.9 years). A total of 117 extrapancreatic findings were observed, most frequently in the liver, including cysts (29%), adenoma/FNH (9%) and hemangioma (21%) (Table 2). One patient underwent an additional ultrasonography and a fine-needle aspiration–biopsy because of a suspected lesion in the liver that proved to be an FNH.

Incidentalomas in the adrenal glands (adrenaloma) were identified in 12 cases (10.3%). In two of the 12 cases the lesion was removed during pancreatic surgery for a solid lesion. The first patient was a 40-year-old homozygote *p16-Leiden* carrier with a solid lesion in the uncinata process of the pancreas, together with a mass in the right adrenal gland detected on the first MRI. CT confirmed both lesions and defined the adrenal mass as an adrenaloma of 3.5 cm. A pancreaticoduodenectomy was performed and the adrenal mass was resected. Pathological examination revealed a PDAC and an adrenal adenoma without evidence of malignancy.

The second patient was a 66-year-old woman who came for her first MRI scan. The MRI showed a mass

in the adrenal gland of 2.4 cm, together with a 1 cm hypovascular mass in the uncinata process. Subsequent CT confirmed both lesions but could not define the adrenal mass. The patient underwent a pancreaticoduodenectomy and an adrenalectomy. Pathological examination showed an intraductal papillary mucinous neoplasm with low-grade dysplasia, and an adrenaloma of 2.4 cm with adrenocortical hyperplasia.

Other frequently detected lesions are shown in Table 2. In seven cases (3.2%) various cancers were found outside the pancreas including two renal cell carcinomas, one colorectal cancer (CRC), a neuroendocrine carcinoma in the liver, a stromal tumor in the stomach and metastases of breast cancer and melanoma. Details of these findings are summarized in Table 3. In four of these patients the early detection of cancer was beneficial.

Madrid, Spain

Eighty-three IARs were under surveillance, consisting of 37 men (44.6%) and 46 women (55.4%). The analyzed cohort included a number of high-risk groups. Forty-two belonged to FPC families, five individuals had a first-degree relative with PDAC younger than 50 years, 19 belonged to a hereditary breast ovarian cancer (HBOC) family, one individual was a *BRCA2* carrier, one belonged to a Lynch syndrome family, two had a *CDKN2A-p16-Leiden* mutation, one belonged to a family with evidence of combined FPC, Lynch syndrome and HBOC, and two belonged to a family with mixed FPC/HBOC. The mean age at start of surveillance was 50 years (range, 29–81 years), with a median follow-up time of 2.9 years (range, 0.1–6.7 years). In total, 122 incidental lesions were detected in 83 individuals (Table 2). Liver cysts (29.5%) were the most commonly found lesions and renal cysts were the second most common finding (19.7%).

In none of the patients was surgical management required. There was one patient who required additional imaging after a solid renal tumor was found (0.8%), but the lesion was characterized as an angioliipoma.

Marburg, Germany

Of the 268 IARs under surveillance in Marburg during the study, 109 were men (40.7%) and 159 were women (59.3%). Average age at start of screening was 48 years (range, 25–75 years) and the median follow-up time was three years (range, 0.1–14.6 years). The cohort included 240 individuals with FPC, four *BRCA1* mutation carriers, 10 *BRCA2* carriers, seven *PALB2* mutation carriers, four *CDKN2A/p16-Leiden* mutation carriers, two *STK11* mutation carriers and one patient with familial

Table 2. Total number of incidental extrapancreatic lesions in the three European cohorts.

Lesions	Leiden	Madrid	Marburg	Total (%)
Hemangioma liver	25	5	25	55 (12.0%)
Adenoma/FNH liver	10	-	3	13 (2.8%)
Cyst liver	34	36	100	170 (37.0%)
Cyst kidney	17	24	75	116 (25.3%)
Cyst breast	2	-	1	3 (0.7%)
Adrenal lesion	12	2	12	26 (5.7%)
Aortic aneurysm	3	-	-	3 (0.7%)
Cancer	7	-	4	11 (2.4%)
Other lesions	7	55	-	62 (13.5%)
Total number of lesions	117	122	220	459 (100%)

FNH: focal nodular hyperplasia.

Table 3. Characteristics of extrapancreatic cancers (or metastatic disease) detected by the Leiden program for PDAC.

Patient no.	M/F	Type of cancer (detected at first screening or during follow-up)	Age at diagnosis (y)	Year of diagnosis	Incidental MRI findings	Stage	Treatment	Status at 1 January 2018 (alive/dead/cause of death)
1	F	Metastases of BC (follow-up)	57	2011	Pleural effusion due to metastatic BC	Metastatic disease	Chemotherapy	Died 2015 of metastatic BC
2	F	Grawitz tumor (follow-up)	60	2014	Left lower kidney mass of 2.3 cm	Fuhrman grade 2, no metastasis, no angioinvasion, cutting edges free	Nephrectomy	Alive
3	M	NEC, primary site unknown (follow-up)	58	2016	Mass in left liver lobe of 53 mm	Metastasized NEC	No treatment possible	Died 2016 of aggressive NEC with metastases in adrenal gland, liver, lungs and bones
4	F	Tubulocystic renal cell carcinoma (first screening)	46	2016	Left kidney lesion with thick walls and septae of 3.4 cm	Grade 3	Nephrectomy	Alive
5	M	GIST (follow-up)	65	2016	Growth of a submucosal lesion in stomach	T2N0M0	Local wedge resection	Alive
6	M	Metastases of melanoma (follow-up)	59	2009	Ascites, peritoneal masses and two hypervascular lesions in liver	Metastatic disease	Chemotherapy	Died 2010, after initial good response on chemotherapy; developed secondary intradural metastases
7	M	Liver metastases of sigmoid carcinoma (follow-up)	56	2014	Two liver lesions	Liver metastases	Sigmoid resection and hepatectomy with neoadjuvant chemotherapy	Alive

BC: breast cancer; F: female; GIST: gastrointestinal stromal tumor; M: male; MRI: magnetic resonance imaging; NEC: neuroendocrine carcinoma; PDAC: pancreatic ductal adenocarcinoma; y: years.

adenomatous polyposis with PDAC. A total of 220 lesions were identified in the 268 patients (Table 2). The most common findings were cysts in the liver (45.5%) or kidney (34.1%). Adrenaloma were observed in 12 cases (5.4%). Liver cysts in two patients and a renal cyst in one patient (1.1% of all patients) required surgical removal.

Regarding the need for additional investigations, the two patients who had surgery for liver lesions had an additional contrast-enhanced ultrasonography. Another 47-year-old man had an additional gastroscopy because EUS gave a suspicion of a MALT (mucosa-associated lymphoma tissue) lymphoma, which was a peptic ulcer. In a 43-year-old woman, a mammography was performed because MRI showed contrast-enhancing lesions in both breasts. Mammography diagnosed fibroadenomas. In another 51-year-old female patient, a 53 × 50 mm solid liver lesion on MRI was further evaluated by contrast-enhanced ultrasonography, which confirmed a hemangioma.

Cancer was identified in four (1.5%) patients (Table 4). The first patient was a 55-year-old woman who underwent surgery for breast cancer in 2004. Undergoing screening for pancreatic cancer 12 years later, MRI revealed multiple lesions in the right ilium and lumbar spine that proved to be bone metastases of breast cancer.

The second patient was a 60-year-old woman undergoing MRI surveillance in 2011. The MRI showed a lesion in the liver, with cholestasis and periportal edema. This lesion turned out to be a bile duct carcinoma (Bismuth stage IIIa). The patient underwent extended liver resection but unfortunately died two weeks later of postoperative liver failure.

The third patient was a 48-year-old female patient who underwent surgery because of breast cancer in 2014. A year later the patient underwent pancreatic cancer screening. MRI showed multiple lesions of the thoracic and lumbar spine, which proved to be bone metastases of the breast cancer. One year later, liver metastases were detected. The patient is still alive.

The detection of the cancers (or metastatic cancers) by the PDAC screening program did not result in a cure for any of these three patients.

The fourth patient, a 52-year-old man, showed a 15 mm, partially cystic cortical lesion of the left kidney with thick walls. This lesion was resected and turned out to be a renal cell carcinoma. The patient is alive without evidence of disease at last follow-up.

Discussion

The present study shows that MRI-based pancreas surveillance programs for PDAC result in the detection of

Table 4. Characteristics of extrapancreatic cancers (or metastatic disease) detected by the German program for PDAC.

Patient no.	M/F	Type of cancer (detected at screening or during follow-up)	Age at diagnosis (y)	Date of diagnosis	MRI findings	Stage	Treatment	Status at 1 January 2018 (alive/dead/cause of death)
1	F	Multiple bone metastases of BC (follow-up)	55	BC 2004, metastases detected 2016	Contrast-enhancing lesions of right ilium and lumbar spine	Metastatic disease (add)	Chemotherapy	Alive with disease
2	F	Klatskin tumor (follow-up)	60	2011	Growing liver lesion, cholestasis, periportal edema	Bismuth IIIa	Trisectectomy	Died two weeks post-operatively of liver failure
3	F	Multiple liver and bone metastases of BC (first screening)	47	BC in 2014, metastases detected October 2015 (bone) and May 2016 (liver)	Multiple new and growing liver lesions, multiple new and growing lesions of thoracic and lumbar spine	Metastatic disease	Chemotherapy	Alive with disease
4	M	Renal cell carcinoma (first screening)	52	2015	Partially cystic cortical lesion of left kidney with thick walls (15 mm)	pT1a, N0, M0, L0, V0, G2, R0	Local resection	Alive without evidence of disease

BC: breast cancer; F: female; M: male; PDAC: pancreatic ductal adenocarcinoma; y: years.

a large number of incidental lesions. The most commonly found lesions were liver cysts, renal cysts and liver hemangioma, which together accounted for 74% of all incidental lesions, followed by adrenal incidentaloma in 6% of patients. Only five (0.9%) patients underwent surgery for a benign lesion: two patients for a liver cyst, one for a renal cyst and two for an adrenal incidentaloma.

Cancer was detected in 11 patients (1.9%), including seven *CDKN2A-p16-Leiden* mutation carriers, and metastatic disease was detected in six of the 11 patients. Early detection of tumors was beneficial in at least five of the patients.

Several studies have reported frequencies of incidental findings detected during abdominal imaging. One study reported the rate of incidental findings of whole-body MRI in 148 healthy control participants.¹¹ The most frequently found abnormalities were renal cysts (42.9%), gallstones (12.2%) and liver cysts/hemangioma (10.2%). In a similar study whole-body MRI was performed in 118 healthy individuals.¹² A total of 106 incidental lesions were found in the 83 individuals with an abnormality, the most common lesions being renal cysts (16.0%), liver hemangioma (12.3%) and liver cysts (11.3%). These findings are in agreement with our findings for benign lesions. However, the rate of incidentally detected cancers in the subgroup of *CDKN2A-p16-Leiden* mutation carriers was much higher.

What was the benefit of the detection of incidental lesions in our study? Although incidental findings were frequent, only 0.9% of the total group of IARs underwent a surgical intervention for a lesion, which was then found to be benign in all cases. A primary cancer, metastases of a previous cancer or a new cancer was detected in 1.9%. By contrast, in the Leiden cohort of *CDKN2A-p16-Leiden* mutation carriers, extrapancreatic cancer was detected in a substantial proportion of patients (seven patients out of 217 (3.2%)). The early detection of cancers in seven mutation carriers allowed curative resection of renal cancers in two patients, a gastric stromal tumor in one patient and colonic resection (and early start of chemotherapy) in one patient with CRC. In the German cohort, the detection of a renal cell carcinoma allowed curative resection. In addition, the identification of metastatic breast cancer in two patients allowed the early start of chemotherapy.

Strengths of the current study include the substantial size of the study group, the wide variation of high-risk groups and the long follow-up time. A possible limitation was that we are not informed about which definitions were used for a significant incidentaloma in the three expert centers and which guidelines for their management.

What are the clinical implications of our findings? First, it is important to inform all participants at the

start of the surveillance program about the possibility of detecting incidental lesions. Based on our findings, it might be explained to patients that lesions are almost always harmless and will not require additional treatment. However, carriers of a *CDKN2A-p16-Leiden* mutation should be told that cancer might be detected outside the pancreas in a small proportion of patients.

To improve the investigation of the pancreas, there is currently a trend toward restricting MRI scanning to the pancreas only. However, to avoid missing cancers located outside the pancreas in *CDKN2A-p16-Leiden* mutation carriers, MRI assessment should include at least one scan of all abdominal organs.

In summary, the present study demonstrates that incidentaloma is a common finding in IARs for PDAC, but rarely requires additional treatment. *CDKN2A-p16-Leiden* mutation carriers were the only patient group found to harbor a substantial number of cancers, and detection resulted in benefit in several cases.

Acknowledgments

We thank Prof A. Mahnken for reading the MRIs, and Thomas Gress, Christian Bauer and Tobias Grote for comparing EUS and MRI results. We are thankful for the grant support of the Deutsche Krebshilfe (no. 111092) and a generous donation from the Gauff-Foundation.

Declaration of conflicting interests

None declared.

Ethics approval

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the ethics committees of the respective participating centers.

Funding

This work was supported by a grant from the Deutsche Krebshilfe (no. 111092) to DKB and EPS, and a donation from the Gauff-Foundation to DKB.

Informed consent

Oral or written informed consent was received from all patients.

ORCID iD

Isaura S Ibrahim  <http://orcid.org/0000-0002-6457-1502>

References

1. Ehrh D, Rothaug K, Herzog P, et al. "Incidentaloma" of the liver: Management of a diagnostic and therapeutic dilemma. *HPB Surg* 2012; 2012: 891787.
2. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; 96: 894–904.

3. Whelan TF. Guidelines on the management of renal cyst disease. *Can Urol Assoc J* 2010; 4: 98–99.
4. Khalid A and Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. *Am J Gastroenterol* 2007; 102: 2339–2349.
5. Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US Society of Radiologists in Ultrasound consensus conference statement. *Ultrasound Q* 2010; 26: 121–131.
6. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a *p16-Leiden* mutation. *Gastroenterology* 2011; 140: 850–856.
7. Vasen H, Ibrahim I, Ponce CG, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers. *J Clin Oncol* 2016; 34: 2010–2019.
8. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): Ten years experience. *Fam Cancer* 2011; 10: 323–330.
9. Mocci E, Guillen-Ponce C, Earl J, et al. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. *Eur J Cancer* 2015; 51: 1911–1917.
10. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. *Gut* 2009; 58: 1410–1418.
11. Morin SH, Cobbold JF, Lim AK, et al. Incidental findings in healthy control research subjects using whole-body MRI. *Eur J Radiol* 2009; 72: 529–533.
12. Ulus S, Suleyman E, Ozcan UA, et al. Whole-body MRI screening in asymptomatic subjects; preliminary experience and long-term follow-up findings. *Pol J Radiol* 2016; 81: 407–414.